@article{7f2baf75e4da4bbeb82d216a14a37ff8,
title = "Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?",
author = "Weinshenker, {Brian G.} and Carroll, {William M.}",
note = "Funding Information: Dr. Weinshenker serves on data safety monitoring boards for Novartis and Biogen Idec; serves on the editorial boards of the Canadian Journal of Neurological Sciences and the Turkish Journal of Neurology ; has received research support from Genzyme Corporation and the Guthy-Jackson Charitable Foundation; and receives license royalties from RSR Ltd. for a patent re: Aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica. Dr. Carroll serves on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, Bayer Schering Pharma, and Yahukin; has received funding for travel or speaker honoraria from Bayer Schering Pharma, Yahukin, Novartis, Biogen Idec, and sanofi-aventis; serves as Editor, Asia-Pacific for Multiple Sclerosis Journal ; and receives publishing royalties for International Neurology (Wiley Blackwell, 2009). ",
year = "2011",
month = aug,
day = "30",
doi = "10.1212/WNL.0b013e31822b012a",
language = "English (US)",
volume = "77",
pages = "812--813",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",
}